Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Accumulated Expenses (2020 - 2026)

MoonLake Immunotherapeutics' Accumulated Expenses history spans 7 years, with the latest figure at $21.8 million for Q1 2026.

  • Quarterly Accumulated Expenses rose 106.91% to $21.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $21.8 million through Mar 2026, up 106.91% year-over-year, with the annual reading at $14.7 million for FY2025, 21.42% up from the prior year.
  • Accumulated Expenses came in at $21.8 million for Q1 2026, up from $14.7 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $21.8 million in Q1 2026 to a low of $30000.0 in Q1 2022.
  • The 5-year median for Accumulated Expenses is $6.9 million (2023), against an average of $8.4 million.
  • Year-over-year, Accumulated Expenses crashed 50.0% in 2022 and then surged 10889.46% in 2023.
  • MoonLake Immunotherapeutics' Accumulated Expenses stood at $7.3 million in 2022, then decreased by 4.5% to $6.9 million in 2023, then soared by 74.59% to $12.1 million in 2024, then increased by 21.42% to $14.7 million in 2025, then soared by 48.49% to $21.8 million in 2026.
  • Per Business Quant, the three most recent readings for MLTX's Accumulated Expenses are $21.8 million (Q1 2026), $14.7 million (Q4 2025), and $21.6 million (Q3 2025).